Vollständiger Abstract
Worum geht es in dieser Arbeit?
AbstractThe high cost of many new anticancer medicines significantly impedes breakthrough discoveries from reaching patients. A commonly heard refrain is that high prices are necessary to compensate for the high costs of research and development (R&D). Yet, there are promising policy proposals aimed at improving affordability without compromising innovation. In seeking new policy solutions, we argue for a shift away from entrenched opinion toward an evidence-based discourse that is grounded in experiments and real-world pilot studies. We offer a novel perspective and practical recommendations on how empirical evidence could and should be gathered to inform evidence-based policy interventions that lead to sustainable medicine prices in oncology.See related article by Franzen et al. (Cancer Res Commun 2022;2:39–47).
Bibliografischer Nachweis
Publikationsdaten
- Autor:innen
- Nora Franzen, Giorgia Romagnoli, Andreas Ziegler, Valesca P. Retèl, Theo J.S. Offerman, Wim H. van Harten
- Quelle
- American Association for Cancer Research (AACR)
- Publikation
- 2023-01-01
- Band / Ausgabe
- Nicht angegeben
- Seiten
- Nicht angegeben
- ISSN / ISBN
- Nicht angegeben
- Zitationen
- 0 laut Crossref
- Referenzen
- 0 hinterlegt
Zitieren
Zitierfähiger Nachweis
Nora Franzen, Giorgia Romagnoli, Andreas Ziegler, Valesca P. Retèl, Theo J.S. Offerman, Wim H. van Harten (2023). Data from Improving the Affordability of Anticancer Medicines Demands Evidence-Based Policy Solutions. https://doi.org/10.1158/2767-9764.crc-26-0322
Kontext
Themen, Förderung und Nutzung
Lizenzhinweise: Lizenz 1